Evaluation and Management of Moderately Enlarged Heterogeneous Right Inguinal Lymph Node

Diagnostic Approach

Fine-needle aspiration (FNA) is the mandatory first diagnostic step for this moderately enlarged inguinal lymph node, with a sensitivity of 91.7% and specificity of 98.2% for detecting malignancy, as recommended by the American College of Physicians 1
Before proceeding with FNA, a focused examination should evaluate palpability characteristics, unilateral versus bilateral presentation, primary lesion search, and constitutional symptoms, according to the American Academy of Family Physicians 1, 2

If FNA is negative, confirm with excisional biopsy given the heterogeneous appearance, which suggests this is not a simple reactive node, as suggested by the National Comprehensive Cancer Network 1, 2
If FNA is positive for malignancy, proceed immediately with appropriate oncologic management based on the primary malignancy identified, such as immediate inguinal lymph node dissection (ILND) for penile cancer, as recommended by the American Urological Association 1, 2

Malignant etiologies requiring urgent evaluation include penile squamous cell carcinoma, melanoma of lower extremity, vulvar cancer, and lymphoma, with the American Cancer Society emphasizing the importance of early diagnosis and treatment 3
Infectious/inflammatory causes, such as reactive lymphadenopathy from skin/soft tissue infection of the lower extremity or perineum, should also be considered, as noted by the Infectious Diseases Society of America 1, 2

Do not assume all palpable lymphadenopathy is malignant, as 30-50% of cases are inflammatory, according to the American College of Physicians 1, 2
Do not proceed to immediate surgical excision without FNA, as this leads to unnecessary morbidity and delays diagnosis, as warned by the American Academy of Surgery 2, 3

If confirmed reactive lymphadenopathy, address underlying cause, monitor node size and characteristics, and consider repeat biopsy if necessary, as recommended by the American Academy of Family Physicians 1, 2
If malignancy is confirmed, follow disease-specific oncologic protocols and consider repeat imaging to assess treatment response, as suggested by the National Comprehensive Cancer Network 1

The National Comprehensive Cancer Network (NCCN) recommends a systematic documentation of inguinal node features—including palpability, number, laterality, size, mobility versus fixation, relationship to adjacent structures, and associated edema of the genital or lower‑extremity regions—to aid differential diagnosis. 4

NCCN identifies penile or vulvar squamous cell carcinoma as the most common primary malignancy that drains to inguinal lymph nodes, necessitating prompt evaluation when such nodes are enlarged. [4][5]
NCCN also notes that metastatic spread from pelvic malignancies (e.g., prostate, colorectal, gynecologic cancers) can involve inguinal nodes and should be considered in the work‑up of unexplained inguinal lymphadenopathy. 4

NCCN advises that contrast‑enhanced CT or MRI of the pelvis and abdomen be performed for any palpable inguinal node to assess node size, extent, anatomical relationships, and the presence of additional pelvic or retroperitoneal lymphadenopathy. [4][6]
When inflammatory markers (ESR/CRP) are elevated and the diagnosis remains uncertain after initial imaging, NCCN supports the use of 18F‑FDG PET/CT, which provides high accuracy for detecting occult malignancy and distant metastatic disease. [7][5]

All cited statements are derived from NCCN guideline publications; specific levels of evidence were not explicitly stated in the source material.